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Plasma triiodothyronine (fT3) is a strong predictor of adverse
clinical outcomes in various clinical conditions. Since fT3 in
patients with end-stage renal diseases (ESRD) is frequently
reduced and is associated with inflammation and
cardiovascular damage, we prospectively tested the
hypothesis that it predicts death in a cohort of 200
hemodialysis patients. Plasma fT3 was lower in ESRD patients
(Po0.001) than in healthy subjects and in clinically euthyroid
patients with normal renal function. During the follow-up
102 patients died. Patients who died had significantly lower
plasma fT3 than those who survived (Po0.001) and in a
Kaplan–Meyer analysis plasma fT3 was associated with death
(Po0.001). On multivariate Cox’s regression analyses,
adjusting for a series of traditional and emerging risk factors
including inflammation markers, patients with relatively
higher plasma fT3 (hazard ratio (HR) (1 pg/ml increase in fT3))
had a 50% reduction in the risk of death (HR¼ 0.50, 95% CI:
0.35–0.72) as compared to those having relatively lower fT3
levels. Of note, plasma fT3 captured most of the predictive
power of interleukin-6 (IL-6) because this latter variable
emerged as a significant predictor of death only in a model
excluding fT3. Low fT3 is an independent predictor of death
in hemodialysis patients. These data lend support to the
hypothesis that thyroid dysfunction is implicated in the high
risk of the ESRD population.
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End-stage renal disease (ESRD) is a frequent cause of ‘non-
thyroidal illness (NTI),’1,2 the definition now preferred to
‘euthyroid sick syndrome’ to denote altered thyroid hor-
mones in the absence of underlying intrinsic thyroid
disorder. Low free triiodothyronine (fT3), the biologically
active form of thyroid hormone, is a major feature of this
disturbance which is considered as a counter-regulatory
response finalized at minimizing energy and protein wasting
in acute and chronic stressful conditions. NTI is indeed
commonly found in systemic illnesses such as acute and
chronic infections, poorly controlled diabetes mellitus with
ketoacidosis, myocardial infarction and severe myocardial
ischemia, and virtually in any severe illness. Thyroid function
is frequently altered in ESRD patients and about 1/4–1/5 of
patients with ESRD display low fT3.3,4 As also reflected by the
new designation of the syndrome, non-NTI is now perceived
as a condition less innocent than previously thought.5 The
pathogenesis of low T3 in NTI is complex and recent
evidence indicates that inflammation plays a central role in
this syndrome.6–8 In a recent survey, we have shown that low
fT3 is associated to inflammation and to cardiovascular
damage in ESRD patients.4 This observation suggests that
low levels of this hormone may denote an unfavorable
prognosis, a hypothesis in keeping with an extensive series of
observations in patients with heart disease9–11 and in various
acute12,13 and chronic diseases14,15 indicating that low fT3 is
one of the strongest markers of poor prognosis in these
conditions. As a part of the original study design, we planned
to prospectively test the hypothesis that fT3 predicts survival
in ESRD patients. To this end, we undertook a follow-up
study in the original cohort where the above-mentioned
observations were made. The results of this study show that
low fT3 is a strong and independent marker of death in
dialysis patients thus implicating this alteration in the high
mortality of ESRD.
RESULTS
The main demographic, somatometric, clinical, and bio-
chemical characteristics of patients included in the study are
detailed in Table 1. A total of 102 patients had had at least
one cardiovascular event (myocardial infarction, electro-
cardiogram-documented anginal episodes, peripheral artery
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disease, arrhythmia transient ischemic attacks, and stroke).
All patients were clinically euthyroid.
Plasma fT3 was significantly (Po0.001) lower in ESRD
patients (3.370.8 pg/ml) than in healthy subjects
(3.771.0 pg/ml) and clinically euthyroid patients with
normal renal function (3.670.8 pg/ml). Average plasma free
thyroxine (fT4) in ESRD patients (1.2370.25 ng/100 ml) was
very similar to that found in healthy subjects (1.2570.22 ng/
100 ml). Fifteen ESRD patients (i.e. 7.5%) had thyroid-
stimulating hormone (TSH) above the upper limit of the
normal range (cutoff: 3 mIU/L). In Table 1 risk factors in
dialysis patients are presented in relationship to fT3 tertiles.
Patients in the first tertile (i.e., those with relatively
lower plasma fT3 levels) were older, included a greater
proportion of individuals with previous cardiovascular
events and of diabetics, and displayed lower hemoglobin
and serum albumin and higher serum interleukin-6
(IL-6) and C-reactive protein (CRP) when compared
to those in other tertiles. The proportion of erythropoietin-
independent patients was similar across fT3 tertiles
(Table 1).
Thyroid hormones and survival
During the follow-up period, 102 patients died, 68 of them
(i.e., 66% of total deaths) of cardiovascular complications
(Table 2). Patients who died (3.170.7 pg/ml) had signifi-
cantly lower plasma fT3 (Po0.001) than those who survived
(3.770.8 pg/ml). Neither fT4 nor TSH were associated with
death (P¼ 0.37 and 0.23, respectively) and for this reason
further analysis was restricted to fT3.
In a Kaplan–Meyer analysis fT3 tertiles were associated
with death (log-rank test 25.3, Po0.001) (Figure 1) and an
Table 1 | Main demographic, clinical, and biochemical data of dialysis patients
Plasma fT3
I tertile (o2.9 pg/ml)
(n=66)
II tertile
(3.0–3.8 pg/ml)
(n=66)
III tertile
(43.8 pg/ml)
(n=68)
P-value
for trend
Age (years) 67712 60714 55716 o0.001
Male sex, n (%) 35 (53%) 30 (45%) 40 (59%) 0.50
Dialysis vintage (months) 38 (24–99) 50 (25–112) 39 (14–87) 0.27
Smokers, n (%) 18 (27%) 25 (39%) 28 (41%) 0.09
Diabetes, n (%) 19 (29%) 11 (17%) 5 (7%) 0.001
On antihypertensive treatment, n (%) 18 (27%) 22 (33%) 20 (29%) 0.79
EPO-independent patients, n (%) 27 (41%) 33 (50%) 35 (51%) 0.38
With previous CV events, n (%) 44 (67%) 34 (52%) 24 (35%) o0.001
Systolic pressure (mm Hg) 141728 144724 134724 0.11
Diastolic pressure (mm Hg) 73713 79714 75712 0.17
Heart rate (beats/min) 78711 7778 79711 0.54
Hemoglobin (g/l) 103719 110716 110720 0.03
Albumin (g/l) 3974 4274 4474 o0.001
Calcium* phosphate (mmol2/l2) 4.4571.01 4.4071.20 4.5771.07 0.45
Homocysteine (mmol/l) 29 (20–43) 26 (21–38) 27 (17–48) 0.97
Cholesterol (mmol/l) 5.3471.15 5.1771.48 5.6471.63 0.36
CRP (mg/l) 13.7 (4.3–25.9) 8.2 (3.4–19.1) 3.8 (3.4–9.5) o0.001
IL-6 (pg/ml) 9.4 (4.6–15.1) 4.2 (2.6–6.3) 3.3 (2.2–6.1) o0.001
ADMA (mmol/l) 2.23 (1.48–3.97) 2.18 (1.33–3.59) 2.52 (1.71–3.96) 0.54
fT4 (ng/100 ml) 1.2 (1.1–1.4) 1.2 (1.1–1.4) 1.1 (1.0–1.3) 0.13
TSH (mIU/l) 1.4 (0.8–1.9) 1.4 (1.0–2.1) 1.2 (1.0–1.3) 0.45
ADMA, asymmetric dimethylarginine; CRP, C-reactive protein; EPO, erythropoietin; fT4, free thyroxine; IL-6, interleukin-6; TSH, thyroid-stimulating hormone.
Data are expressed as mean7s.d., median and inter-quartile range or as percent frequency, as appropriate.
Values given in bold identify statistically significant differences.
Table 2 | Causes of death in the study cohort
Causes of death n
Cardiovascular
Stroke 18
Heart failure 12
Myocardial infarction 17
Mesenteric infarction 5
Arrhythmia 4
Sudden death 8
Pulmonary embolism 3
Peripheral vascular disease 1
Other causes
Cachexia 8
Sepsis/infection 11
Neoplasia 4
Hyperkalemia 3
Gastrointestinal hemorrage 3
Chronic obstructive pulmonary disease 1
Diabetes, hyperosmolar coma 1
Treatment withdrawal 1
Liver cirrhosis 1
Hemoptysis 1
Total 102
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association of similar strength was observed also in an
univariate (unadjusted) Cox analysis with plasma fT3 as
continuous variable (Table 3, Model 1). On multivariate Cox
regression analysis, plasma fT3 remained a significant
predictor of all-cause death (Table 3). Indeed, both in
statistical models adjusting for age and sex (Model 2) and
in fully adjusted models including potential confounders
identified in Table 1 and univariate predictors of death (age,
male sex, smoking, diabetes, previous cardiovascular events,
systolic pressure, albumin, and asymmetric dimethylarginine
(ADMA)) the strength of the association between plasma fT3
and death (Table 3, Model 3) remained strong and
significant. In this analysis, patients with relatively higher
plasma fT3 levels (1 pg/ml increase), had a fully adjusted
relative risk for all-cause death by the 50% lower (HR: 0.50,
95% CI: 0.35–0.72; Po0.001) than that observed in those
with relatively lower values. IL-6 failed to predict survival in
the fully adjusted multivariate Cox’s model (Table 3, Model
3). Interestingly, plasma fT3 captured most of the predictive
power of IL-6 because this latter variable emerged as a
significant predictor of death (HR (10 pg/ml increase in
IL-6): 1.25, 95% CI: 1.01–1.54) only in a model excluding
fT3. Accordingly, the prognostic overlapping of the two risk
factors was of significant magnitude (21%).
DISCUSSION
This study shows that low fT3 is an independent predictor of
death in hemodialysis patients. These data lend support to
the hypothesis that thyroid dysfunction may be implicated in
the high risk of the ESRD population.
Derangements in thyroid function in ESRD and in the study
cohort
Thyroid hormone metabolism is disturbed at multiple critical
steps in patients with chronic renal disease including iodine
accumulation in the thyroid gland, protein binding and
peripheral tissue metabolism (e.g., altered de-iodination),
actual tissue concentration and availability.2,3 It was
hypothesized that subnormal free T3 in ESRD may be due
to the accumulation of substances that inhibit binding of T3
to the solid-phase matrices. We found that fT3 but not fT4
was reduced in ESRD patients suggesting that low fT3 is
unlikely to be an in vitro artifact because substances
inhibiting binding are expected to affect fT4 to a greater
extent than fT3. Thus, reduced fT3 seems to reflect a true
selective T3 deficiency due to a defect in T4 to T3 conversion.
It is important noting that reduced fT3 does not entail a
condition of subclinical hypothyroidism because, as in a
previous study,16 we found that TSH and fT4 are in the
normal range in the majority of patients with this alteration.
However, low fT3 most likely may not be an innocent finding
because it is a most consistent predictor of death in various
diseases9,11,12 and depressed fT3 is associated with inflamma-
tion and cardiovascular damage in ESRD.4 In the present
study, we have therefore tested the hypothesis that low fT3
predicts death in a well-characterized study cohort of ESRD
patients.
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Figure 1 | Kaplan–Meier survival analysis of plasma fT3. Patients
are grouped into three tertiles on the basis of individual values of
plasma fT3. In parentheses we reported the HR of death (and the 95%
CI) associated to each fT3 tertile.
Table 3 | Crude and adjusted relative risks of plasma fT3 for all-cause mortality
All cause mortality relative risks (95% CI), P-values
Variables (units of increase) Model 1 (unadjusted) Model 2 (age and sex adjusted) Model 3 (fully adjusted)
Plasma fT3 (1 pg/ml) 0.45 (0.34–0.60), Po0.001 0.52 (0.39–0.69), Po0.001 0.50 (0.35–0.72), Po0.001
Age (1 year) — 1.05 (1.03–1.07), Po0.001 1.06 (1.04–1.08), Po0.001
Male sex — 1.97 (1.32–2.95), P=0.001 1.74 (1.03–2.93), P=0.04
Diabetes — — 1.66 (1.03–2.66), P=0.04
Previous CV events — — 1.76 (1.12–2.77), P=0.01
Hemoglobin (1 g/l) — — 1.01 (0.99–1.02), P=0.10
IL-6 (10 pg/ml) — — 1.03 (0.82–1.31), P=0.79
Smoking — — 1.47 (0.87–2.49), P=0.15
Systolic pressure (1 mm Hg) — — 1.00 (0.99–1.01), P=0.94
Albumin (1 g/l) — — 0.99 (0.94–1.04), P=0.76
ADMA (1mmol/l) — — 1.24 (1.13–1.37), Po0.001
ADMA, asymmetric dimethylarginine; CRP, C-reactive protein; CV, cardiovascular; fT3, triiodothyronine; IL-6, interleukin-6.
Data are expressed as hazard ratio (95% CI) and P-value. Because of the collinearity between serum IL-6 and CRP, we included into the fully adjusted Cox model (Model 3) only
serum IL-6. However, the inclusion of serum CRP instead of serum IL-6 did not affect the strength of the association between plasma fT3 and death (HR (1 pg/ml increase in
plasma fT3): 0.51, 95% CI 0.36–0.71, Po0.001). IL-6 emerged as a significant predictor of death (HR (10 pg/ml increase): 1.25, 95% CI: 1.01–1.54, P=0.04) only in a model
excluding fT3 (see text).
Kidney International (2006) 70, 523–528 525
C Zoccali et al.: FT3 in end-stage renal disease o r i g i n a l a r t i c l e
FT3 as a risk marker
FT3 is of crucial importance in adaptive mechanism(s) to
starvation, stress, and severe illness. The reduction of fT3 and
other thyroid hormones in severe illness has been interpreted
in a teleological manner, that is, as an adaptive response
aimed at sparing calories and protein. While this response
does not seem to have detrimental effect in the short term, in
the long term it signals, and probably contributes to cause17 a
high-risk situation. In intensive care patients it predicts 5
days mortality.13 In patients with liver cirrhosis15 or with
severe pulmonary diseases14 it is an indicator of poor
prognosis and in patients with chronic heart failure it
predicts death9,11 and adds prognostic information to
standard parameters of cardiac function including ejection
fraction.10 Furthermore, thyroid dysfunction is associated
with a hypercoagulable status18 and represents a risk factor
for subclinical atherosclerosis in euthyroid hyperlipidemic
patients.19
FT3 and survival in ESRD
The hypothesis that low fT3 is a risk factor for death has
never been tested in patients with ESRD. In general, NTI in
these patients is considered an innocent condition.2 The
cardiovascular system is very sensitive to thyroid hormone
and not only clinical and subclinical hypothyroidism but also
a low T3 syndrome is associated with changes in myocardial
performance10 and death9 in patients with heart failure. By
several analytical approaches we found that fT3 was a
consistent predictor of death and the strength of this
association was little modified by statistical adjustment for
a series of traditional and non-traditional risk factors.
Causality is a complex issue that cannot be resolved only
on the basis of observational data. Statistical models are
useful to generate interpretative hypotheses and it is an
accepted concept that when two risk factors are in the same
pathway one of them may loose predictive power.20,21 FT3
was a highly significant predictor of death in a multivariate
analysis including IL-6 while this cytokine predicted
mortality only in a model excluding fT3. Such a statistical
phenomenon suggests that inflammation and fT3 are in the
same pathogenic pathway leading to death in ESRD patients
(Figure 2) and that fT3 mediates part of the adverse effects of
inflammation in these patients. Yet our interpretation should
be merely considered as hypothesis generating and it remains
to be specifically tested in experimental studies. One may
wonder why IL-6 but not CRP or albumin or ADMA lost
prediction power in the full model including fT3. IL-6 is
considered a purer inflammation marker than CRP which
reflects a larger array of biological phenomena than IL-6. For
example, CRP seems to be directly – that is, independently of
IL-6 – involved in the pathogenesis of arterial damage.22 On
the other hand albumin, an established inverse acute-phase
reactant, reflects also the nutritional status. Furthermore,
ADMA has complex effects on the cardiovascular system, that
is, effects well beyond inflammation.23 Thus, both on
biological and statistical grounds it is not surprising that
CRP, ADMA, and albumin turn out to be independent
predictors of death.
Favorable effects of T3 administration were noted in an
experimental model of myocardial infarction24 and in a small
series of patients with heart failure.25 However, we still lack
long-term studies testing the effect of T3 on mortality in
patients with heart disease and generally in those NTI.
D-Thyroxine administration in dialysis patients reduces the
plasma concentration of lipoprotein(a),26 that is, a lipo-
protein very sensitive to inflammatory processes. However,
near physiologic doses of T3 (50 mg/day) produce a negative
nitrogen balance in these patients.27 Although this effect may
only reflect correction of hypothyroidism and can be
prevented by increasing protein intake, caution is needed in
studies exploring the effect of T3 in ESRD patients. The
important observation that the low fT3 state of ESRD can be
almost fully corrected by appropriate treatment of metabolic
acidosis28 opens an interesting perspective for intervention.
In summary, low fT3 is an independent predictor of death
in hemodialysis patients. These data lend support to the
hypothesis that thyroid dysfunction is implicated in the high
risk of the ESRD population. Mechanistic studies and
exploratory intervention trials in ESRD patients with low
fT3 are at this stage needed to further investigate the nature
of the association between fT3 and clinical outcomes
unravelled by this study.
MATERIALS AND METHODS
The protocol conformed to the ethical guidelines of our institution,
and informed consent was obtained from each participant.
Patients and controls
We studied 200 hemodialysis patients with ESRD (105 men and 95
women, aged 61715 years). This cohort represented all eligible
patients being treated in two dialysis centers sharing the same
practice patterns and serving the same metropolitan area during a
calendar year and all incident patients who entered dialysis
treatment in the same centers during the following 15 months. To
be included in the study, patients had to be free of inter-current
illnesses (infectious diseases, cardio-circulatory congestion, cancer,
and any other diseases requiring hospitalization) and off drugs that
may affect the plasma concentration of thyroid hormones. Eighteen
patients were excluded from the study because they were taking
b-blockers. Patients were being treated thrice weekly with standard
Reduced fT3
Inflammation (IL-6)
Death
Figure 2 | Hypothetic chain of events leading to death. Reduced
fT3 results from inflammation and determines death in ESRD patients.
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bicarbonate dialysis (138 mmol/l Na, 35 mmol/l HCO3, 1.5 mmol/l
K, 1.25 mmol/l Ca, and 0.75 mmol/l Mg) by cuprophane or
semisynthetic membranes (dialysis filters surface area 1.1–1.7 m2).
Dry weight was targeted in each case to achieve a normotensive
edema-free state. The average urea Kt/V in these patients was
1.2070.26. Seventy-one patients were habitual smokers (22716
cigarettes/day). A total of 107 patients were on treatment with
erythropoietin. Sixty patients were on antihypertensive treatment
(48 on mono-therapy with angiotensin-converting inhibitors, AT-1
antagonists, or calcium channel blockers and 12 on double or triple
therapy with various combinations of these drugs). No patient was
assuming lithium, amiodarone, or other drugs that may interfere
with thyroid function and no patient had clinical evidence of
hypothyroidism.
We formed two control groups: one composed of 31 healthy
individuals (recruited from the clinical and laboratory staff and
from a series of healthy senior members of an association that
supports our institution) who were matched accurately (by 5 years
categories) to patients for gender and age (15 men, 16 women,
average age: 61 years). Furthermore, for fT3 measurement only, we
formed an additional control group that comprised 262 clinically
euthyroid individuals (average age: 55 years; range 20–85 years; 136
men and 126 women) who had normal renal function (serum
creatinine o1.2 mg/dl) and were referred consecutively to an
internal medicine clinic for hypertension, gastrointestinal diseases,
or osteoporosis.
Follow-up
After the initial assessment patients were followed up for an average
time of 42 months (range 0.2–70 months). During the follow-up,
fatal cardiovascular events (sudden death, mesenteric and myo-
cardial infarction, electrocardiogram-documented arrhythmia, pul-
monary embolism, heart failure and stroke, and other thrombotic
events except arterio-venous thrombosis) and death of any causes
were accurately recorded. Each event was reviewed and assigned an
underlying cause by a panel of five physicians. As a part of the
review process, all available medical information about each death
was collected. This information always included study and
hospitalization records. In the case of an out-of-hospital death,
family members were interviewed by telephone to better ascertain
the circumstances surrounding death.
Laboratory measurements
Blood sampling was performed between 0800 and 1000 mid-week,
during the dialysis interval. Samples were taken into chilled
ethylenediaminetetraacetic acid vacutainers, placed immediately on
ice, and centrifuged within 30 min at 41C, and the plasma was
stored at 801C until assay. Cholesterol, albumin, calcium,
phosphate, and hemoglobin measurements were made by standard
methods in the routine clinical laboratory. FT3 and fT4 were
measured by a commercially available RIA kits (RIA-coat fT3 and
RIA-mat fT4 by Byk-Sangtek Diagnostica, Dietzenbach, Germany).
In the fT3-RIA coat assay free T3 from serum samples competes
with radioactive-labelled T3 for specific T3 antibodies which are
covalently bound to the inner part of the test tubes. TSH was
measured by a sensitive IRMA (IRMA-mat TSH, Byk-Sangtek
Diagnostica). The intra-assay coefficient of variation of these
hormones ranged from 2.8 to 4.7%; and the inter-assay coefficient
of variation was from 6.5 to 7.1%. The upper limit of TSH of this
assay is 3 mIU/l. The methods of measurement of plasma total
homocysteine, CRP, plasma ADMA and serum IL-6 were reported
elsewhere.29–31 We specifically focused on IL-6 because this cytokine
is the strongest predictor of death among inflammation markers.31
Statistical analysis
Data are reported as mean7s.d., median and inter-quartile range or
as percent frequency, as appropriate, and comparisons among
groups were made by P-value for trend test.
The association between plasma fT3 and all-cause death was
analyzed by the Kaplan–Meier method and by univariate and
multivariate Cox regression analysis. As potential confounders for
the association of fT3 with death we considered a series of
traditional risk factors (age, sex, previous cardiovascular events,
smoking, diabetes, arterial pressure, heart rate, antihypertensive
treatment, and cholesterol), risk factors peculiar to ESRD (dialysis
vintage, albumin, hemoglobin, calcium phosphate, and homo-
cysteine) and emerging risk factors as serum IL-6, serum CRP, and
ADMA. The independent association between plasma fT3 and death
was then analyzed in Cox models of various complexity: unadjusted,
age and sex adjusted, and adjusted for covariates that were either
associated (with Po0.05) to plasma fT3 (see Table 1) or that
resulted to be significantly related (with Po0.05) with survival at
univariate Cox regression analysis. The prognostic overlapping
(degree of confounding) between fT3 and IL-6 was calculated by a
standard method. By this method confounding is considered as
statistically relevant when it exceeds 15%.20
Hazard ratios (HR) and their 95% CI were calculated with the
use of the estimated regression coefficients and their s.e. in the Cox
regression analysis. All calculations were carried out using a
standard statistical package (SPSS for Windows Version 9.0.1, 11
March 1999).
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